Twist Bioscience Corp experienced a significant rise in its stock price, fueled by strategic partnerships and increasing market demand.
Twist Bioscience Corp (NASDAQ:TWST) saw its stock jump by 16.11% yesterday, closing at CA$184.03. This increase follows the announcement of a strategic partnership that positions the company well in the growing AI-driven drug discovery market.
Advertisement
Twist Bioscience Corp
TWST.US
TWST.US
Twist Bioscience Corp
WealthAwesomeMarket cap
$12.20B
52W high
$185.22
52W low
$23.30
1W change
+18.30%
Beta
2.22
Analyst Price Targets
Based on 12 analysts covering TWST · as of Sep 21, 2026
Wall Street analysts forecast TWST stock price to fall 40.5% over the next 12 months.
Consensus
Buy4.17 / 5.00
Avg. Target
C$109.58
-40.5% Upside
Previously C$106.25 on Sep 17, 2026
Current Price
C$184.03
Last close
Analyst Breakdown (12 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TWST's historical volatility
30-Day Vol
99.0%
Annualized
90-Day Vol
87.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$220.01
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$195.32 | C$138.79 – C$274.86 |
| 60 trading days | C$207.30 | C$127.87 – C$336.06 |
| 90 trading days | C$220.01 | C$121.75 – C$397.58 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should consider the potential for growth in Twist Bioscience's revenue as it expands its AI capabilities through partnerships, even though there are risks associated with entering new markets.
16.11%
Twist Bioscience's stock price surged by 16.11% yesterday, reflecting strong investor sentiment after the partnership announcement.
Bull case
The partnership with Lilly TuneLab boosts Twist's credibility and opens up new revenue opportunities in the AI drug discovery sector. This could lead to increased demand for its antibody characterization services.
Bear case
Despite the positive news, the partnership doesn't guarantee immediate revenue, and the fast-paced changes in the market could threaten Twist's profitability if it doesn't effectively meet the growing demand.
Advertisement
Partnership with Lilly TuneLab
Twist Bioscience announced a strategic partnership with Lilly TuneLab, enabling the company to offer antibody characterization data services. This collaboration positions Twist to take advantage of the rising demand for AI-driven drug discovery, potentially increasing its service revenue as more users adopt the TuneLab platform.
Market Reaction and Future Outlook
The market reacted positively to the partnership news, as seen in the 16.11% surge in stock price. Investors are optimistic about Twist's ability to leverage its expertise in antibody characterization to meet the growing demand in the biotechnology sector, although the lack of immediate revenue visibility from the partnership raises some caution.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
